...
search icon
axsm-img

Axsome Therapeutics Inc, Common Stock

AXSM

NMQ

$111.545

-$0.75

(-0.67%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.08B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
123.50K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.88
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$64.11 L
$139.13 H
$111.545

About Axsome Therapeutics Inc, Common Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameAXSMSectorS&P500
1-Week Return7.73%3.49%3.59%
1-Month Return-3.72%-3.79%-0.81%
3-Month Return3.16%-4.66%-8.37%
6-Month Return25.52%-5.16%-4.39%
1-Year Return52.24%0.1%10.47%
3-Year Return229.88%8.49%33.76%
5-Year Return18.16%40.85%90.84%
10-Year Return1184.78%95.89%166.74%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-8.82M50.04M270.60M385.69M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.29,"profit":true},{"date":"2022-12-31","value":12.97,"profit":true},{"date":"2023-12-31","value":70.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue77.72K1.16M5.20M26.07M33.30M[{"date":"2020-12-31","value":0.23,"profit":true},{"date":"2021-12-31","value":3.47,"profit":true},{"date":"2022-12-31","value":15.61,"profit":true},{"date":"2023-12-31","value":78.27,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(77.72K)(1.16M)44.84M244.53M352.39M[{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":-0.33,"profit":false},{"date":"2022-12-31","value":12.72,"profit":true},{"date":"2023-12-31","value":69.39,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin-(13.10%)89.61%90.37%91.37%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-14.34,"profit":false},{"date":"2022-12-31","value":98.08,"profit":true},{"date":"2023-12-31","value":98.91,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses99.09M124.71M221.34M476.36M632.95M[{"date":"2020-12-31","value":15.65,"profit":true},{"date":"2021-12-31","value":19.7,"profit":true},{"date":"2022-12-31","value":34.97,"profit":true},{"date":"2023-12-31","value":75.26,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(99.14M)(124.71M)(176.50M)(231.82M)(280.56M)[{"date":"2020-12-31","value":-9914132800,"profit":false},{"date":"2021-12-31","value":-12470693000,"profit":false},{"date":"2022-12-31","value":-17650082500,"profit":false},{"date":"2023-12-31","value":-23182500000,"profit":false},{"date":"2024-12-31","value":-28056200000,"profit":false}]
Total Non-Operating Income/Expense(6.38M)(11.39M)(14.67M)(12.91M)(13.14M)[{"date":"2020-12-31","value":-637868800,"profit":false},{"date":"2021-12-31","value":-1139212400,"profit":false},{"date":"2022-12-31","value":-1466924700,"profit":false},{"date":"2023-12-31","value":-1290600000,"profit":false},{"date":"2024-12-31","value":-1313800000,"profit":false}]
Pre-Tax Income(102.90M)(130.40M)(187.13M)(238.28M)(287.13M)[{"date":"2020-12-31","value":-10290060000,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23827800000,"profit":false},{"date":"2024-12-31","value":-28713100000,"profit":false}]
Income Taxes2.49M4.54M10.63M960.00K85.00K[{"date":"2020-12-31","value":23.4,"profit":true},{"date":"2021-12-31","value":42.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.03,"profit":true},{"date":"2024-12-31","value":0.8,"profit":true}]
Income After Taxes(105.39M)(134.94M)(197.77M)(239.24M)(287.22M)[{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false},{"date":"2024-12-31","value":-28721600000,"profit":false}]
Income From Continuous Operations(102.95M)(130.40M)(187.13M)(239.24M)(287.22M)[{"date":"2020-12-31","value":-10295417800,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false},{"date":"2024-12-31","value":-28721600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(105.39M)(134.94M)(197.77M)(239.24M)(287.22M)[{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false},{"date":"2024-12-31","value":-28721600000,"profit":false}]
EPS (Diluted)(2.73)(3.47)(4.57)(5.20)(5.99)[{"date":"2020-12-31","value":-273,"profit":false},{"date":"2021-12-31","value":-347,"profit":false},{"date":"2022-12-31","value":-457,"profit":false},{"date":"2023-12-31","value":-520,"profit":false},{"date":"2024-12-31","value":-599.19,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AXSM
Cash Ratio 1.37
Current Ratio 2.11
Quick Ratio 2.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AXSM
ROA (LTM) -27.28%
ROE (LTM) -231.63%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AXSM
Debt Ratio Lower is generally better. Negative is bad. 0.90
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.10

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AXSM
Trailing PE NM
Forward PE NM
P/S (TTM) 13.90
P/B 94.01
Price/FCF NM
EV/R 13.58
EV/Ebitda NM
PEG NM

FAQs

What is Axsome Therapeutics Inc share price today?

Axsome Therapeutics Inc (AXSM) share price today is $111.545

Can Indians buy Axsome Therapeutics Inc shares?

Yes, Indians can buy shares of Axsome Therapeutics Inc (AXSM) on Vested. To buy Axsome Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AXSM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Axsome Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Axsome Therapeutics Inc (AXSM) via the Vested app. You can start investing in Axsome Therapeutics Inc (AXSM) with a minimum investment of $1.

How to invest in Axsome Therapeutics Inc shares from India?

You can invest in shares of Axsome Therapeutics Inc (AXSM) via Vested in three simple steps:

  • Click on Sign Up or Invest in AXSM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Axsome Therapeutics Inc shares
What is Axsome Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Axsome Therapeutics Inc (AXSM) is $139.13. The 52-week low price of Axsome Therapeutics Inc (AXSM) is $64.11.

What is Axsome Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Axsome Therapeutics Inc (AXSM) is 94.01

What is the Market Cap of Axsome Therapeutics Inc?

The market capitalization of Axsome Therapeutics Inc (AXSM) is $5.08B

What is Axsome Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Axsome Therapeutics Inc is AXSM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top